摘要
目的探讨肝动脉栓塞化疗（TACE）对肝癌并发不同类型门静脉癌栓患者的疗效及安全性。方法413例肝癌并发门静脉癌栓（PVTT）患者按是否接受TACE治疗分为TACE组（332例）和对照组（81例），比较两组患者的生存率和治疗效果。结果TACE组3、6、12、24个月生存率分别为93．4％、71．7％、44．9％、24．4％，与对照组的24．7％、2．5％、0、0相比较，差异均有统计学意义（均P〈0．01）；TACE组PVTT类型中Ⅰ型、Ⅱ型、Ⅲ、Ⅳ型各型间治疗有效率比较，差异均有统计学意义（均P〈0．01），以Ⅰ型治疗效果最好，Ⅳ型治疗无效。结论Ⅰ型、Ⅱ型、Ⅲ型PVTT适宜TACE治疗。
Objective To explore the effect of transcatheter hepatic artery chemoembolization（TACE） between different types of liver cancer patients with portal vein tumor thrombus （PVTT）. Methods 413 liver cancer patients with PVTT were divided into two groups,TACE （ 332 cases） group and control group （ 81 cases） ; To compare the survival rate and the curative effect of two group. Results Survival rate in the TACE group of 3 months,6 months, 12 months,24 months were 93. 4% ,71.7% ,44. 9% ,24. 4% , in the control group 3 months,6 months, 12 months,24 months survival rate were 24. 7% , 2.5% ,0,0. The difference has statistical significance （ P 〈 0. 01 ）. In the TACE group, type Ⅰ, Ⅱ , Ⅲ, Ⅳ of PVTT patients treatmented with TACE also has different survival rate and different curative effect（ P 〈 0. 01 ）. Conclusion TACE treatment is particularly effective for type Ⅰ, type Ⅱ and type Ⅲ patients of PVTT.
出处
《中国基层医药》
CAS
2010年第2期158-159,共2页
Chinese Journal of Primary Medicine and Pharmacy
关键词
肝肿瘤
栓塞
治疗性
门静脉
Liver neoplasms
Embolization, therapeutic
Portal vein
